Enzo Biochem (NYSE:ENZ) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Enzo Biochem (NYSE:ENZ) in a report released on Thursday. The brokerage issued a hold rating on the medical research company’s stock.

Enzo Biochem Stock Up 1.8 %

Shares of ENZ opened at $1.15 on Thursday. Enzo Biochem has a 1 year low of $0.99 and a 1 year high of $1.50. The stock has a 50 day simple moving average of $1.13 and a two-hundred day simple moving average of $1.12.

Enzo Biochem Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 15th will be given a $0.10 dividend. This represents a $0.40 dividend on an annualized basis and a yield of 34.78%. The ex-dividend date is Friday, November 15th.

Institutional Investors Weigh In On Enzo Biochem

An institutional investor recently raised its position in Enzo Biochem stock. XTX Topco Ltd grew its stake in shares of Enzo Biochem, Inc. (NYSE:ENZ) by 94.5% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 28,262 shares of the medical research company’s stock after purchasing an additional 13,735 shares during the quarter. XTX Topco Ltd owned approximately 0.05% of Enzo Biochem worth $31,000 at the end of the most recent quarter. 36.90% of the stock is currently owned by institutional investors.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.